Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Reinhart Partners LLC.

Reinhart Partners LLC. reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 3.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,742 shares of the medical research company's stock after selling 1,934 shares during the period. Reinhart Partners LLC. owned approximately 0.10% of Charles River Laboratories International worth $7,337,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after purchasing an additional 14,787 shares in the last quarter. Finally, Ariel Investments LLC increased its position in shares of Charles River Laboratories International by 18.9% during the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after purchasing an additional 169,640 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 2.4%

Shares of CRL stock traded up $3.59 on Tuesday, reaching $151.05. 780,782 shares of the stock were exchanged, compared to its average volume of 998,412. The stock has a market cap of $7.42 billion, a P/E ratio of 1,006.97, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $127.89 and a two-hundred day moving average of $158.11. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period in the prior year, the firm posted $2.27 EPS. The business's revenue for the quarter was down 2.7% on a year-over-year basis. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

CRL has been the topic of a number of research analyst reports. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their target price for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Barclays lifted their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a report on Thursday, May 8th. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a report on Thursday, May 8th. Finally, TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and an average price target of $171.85.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).